Loading…
Loading…
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces the grant of stock options (the "Options") pursuant to its stock option plan to purchase up to an aggregate of 3,300,000 common shares of the Company, subject to TSX Venture Exchange approval, of which 2,500,000 Options were granted to directors and officers, 600,000 Options to employees, and 200,000 Options to consultants of the Company. The Options are exercisable at a price of $0.055 per share and expire five years from the date of grant.
Clinical Study on Track to Meet Primary Endpoints with Interim Data Demonstrating Blood-Based Assay Capable of Predicting Relapse Risk Through Analysis of Genomic Instability and Telomere Architecture Vancouver, British Columbia--(Newsfile Corp. - July 16, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the 3D analysis of telomeres (which are the ends of chromosomes), announced positive interim results from an ongoing retrospective clinical study conducted in collaboration with National and Kapodistrian University of Athens. The clinical trial, which is expected to conclude in summer 2026, analyzes baseline blood samples from multiple myeloma patients treated with standard-of-care regimens.
Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced that it has filed a U.S. provisional patent application seeking to protect a new TeloView® biomarker algorithm for use with liquid biopsy samples, even those with minimal residual disease ("MRD") in the management of patients with multiple myeloma ("MM"). "This filing reflects our continued focus on building intellectual property around high-value applications of the TeloView® platform," said John Farlinger, Telo's CEO.
Vancouver, British Columbia--(Newsfile Corp. - June 26, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces that the investor relations consulting agreement with Sheridan Adams, LLC ("Sheridan"), as announced on March 31, 2026, has been terminated effective June 12, 2026. It was initially understood between the parties that this was a transitory role for Sheridan and was not intended to be long term.
Clinical Trial Seeks to Validate Novel Blood-Based Assay that Predicts Relapse Risk by Analyzing the Biologic Behavior of Remaining Cancer Cells, Addressing Critical Gaps in Current Minimal Residual Disease (MRD) Testing Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the 3D analysis of telomeres (which are the ends of chromosomes) today announced the launch of a new retrospective clinical study in collaboration with leading hematologists at the National and Kapodistrian University of Athens, Dr. Meletios Dimopoulos and Dr. Efstathios Kastritis. The clinical trial will analyze baseline blood samples from multiple myeloma patients treated with standard-of-care regimens.
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, has appointed John Farlinger, currently chair of the Company's audit committee, as chief executive officer and chairman. In connection with Mr.
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement offering (the "Offering") of non-transferable secured convertible debentures ("Debentures") (see news releases dated January 19, 2026, February 18, 2026, and February 27, 2026) by issuing Debentures for gross proceeds of $545,000 (the "Second Tranche"), for aggregate gross proceeds from the Offering of $1,385,000. The Debentures bear interest at a rate of 15% per annum, compounded quarterly, and will mature on December 15, 2026 (the "Maturity Date").
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has increased the size of its previously announced non-brokered private placement of non-transferable secured convertible debentures (the "Debentures") from up to $1,200,000 to up to $1,600,000 (the "Upsized Offering"). The Debentures will bear interest at a rate of 15% per annum, compounded quarterly, and will mature on December 15, 2026 (the "Maturity Date").
No recent filings indexed.